- 2020
-
Press releases - 28.09.2020
Rift Valley Fever: An Example of the Fight Against Emerging Viral Diseases
Maladie virale à l’origine d’épidémies importantes, principalement en Afrique, la fièvre de la Vallée du Rift (FVR) se transmet du bétail à l’humain. Classée maladie prioritaire émergente par le programme R&D Blueprint de l’Organisation Mondiale de la Santé (OMS) en 2015, sa dynamique de transmission avait pourtant jusqu’ici été peu étudiée. Des chercheurs et professionnels de la santé publique de l’Inserm, de Santé publique France et du Cirad avec le soutien du consortium REACTing ont développé un modèle mathématique pour étudier la dynamique de l’épidémie de FVR qui a touché Mayotte en 2018-2019 et quantifier pour la première fois l’impact bénéfique de la vaccination du bétail.
-
Press releases - 17.09.2020
Early Puberty: Is There a Potential Explanation for Some Cases?
A research team from Inserm, Lille teaching hospital and Université de Lille working at the Lille Neuroscience and Cognition Laboratory has discovered in mice a mechanism associated with the prepubertal growth spurt and the triggering of early puberty. This mechanism is regulated by the GnRH neurons, which orchestrate fertility, through the expression of their protein Nrp1.
-
Press releases - 17.09.2020
Consumption of Foods With Lower Nutri-Scores Associated With Higher Mortality
Consuming food products that rank lower on the nutritional quality score underlying the Nutri-Score logo is associated with higher mortality, according to the European cohort EPIC. These findings, obtained by researchers from Inserm, Inrae, Cnam and Université Sorbonne Paris Nord, in collaboration with researchers from the International Agency for Research on Cancer (WHO/IARC), confirm the relevance of Nutri-Score in the context of public health policy.
-
Press releases - 16.09.2020
Research shows that treatment with growth hormone in children who have recovered from cancer does not increase the risk of a second tumor.
Les données d’une nouvelle étude confirment que le traitement par hormone de croissance suite à une radiothérapie chez les enfants qui présentent un déficit de cette hormone n’augmente pas le risque de survenue d’un second cancer.
-
Press releases - 02.09.2020
Prise en charge des formes sévères de Covid-19 : une méta-analyse incluant l’étude CAPE-COVID* plaide en faveur de la corticothérapie
Les résultats d’une méta-analyse montrent qu’un traitement par corticoïdes diminuerait de 21% le risque de mortalité des formes sévères de Covid-19.
-
Press releases - 14.08.2020
A Novel Genome Editing Tool for Rare Hereditary Diseases
Researchers from Inserm, Université d’Evry, Université Paris-Saclay and Genethon have developed a novel platform for modifying the genome of hematopoietic stem cells, which give rise to blood cells. The use of these tools could provide new therapeutic solutions for many patients with rare genetic diseases.
-
Press releases - 29.07.2020
Publication of Explore Covid-19 translationnal study findings
A Marseille-based exploratory research taskforce, named EXPLORE COVID-19, analyzed immune cells in COVID-19 patients at different stages of the disease. The goal of the study was to gain translational insights to better understand the immune response in COVID-19 patients and identify potential targets to fight the viral infection.
-
Press releases - 28.07.2020
The increased reproductive rate of the virus heralding a second wave, really?
While the virus is still circulating throughout the country, fears of a “second wave” are growing. In order to better understand the dynamics of the epidemic, several indicators are taken into account.
-
Press releases - 27.07.2020
COVID-19: Together, Remdesivir and Diltiazem Open up New Therapeutic Avenues
As the COVID-19 pandemic continues, finding a treatment to effectively combat the disease remains a major research challenge. Researchers from Inserm, CNRS, Université Claude Bernard Lyon 1 and ENS Lyon at the International Research Center for Infectious Diseases have developed a unique strategy for selecting, evaluating and repurposing existing drugs to assess their efficacy against SARS-CoV-2.
-
Press releases - 24.07.2020
Ebola Survivors Present Severe Immune System Abnormalities Two Years After Recovery
Four years after the end of the Ebola epidemic in West Africa, and as it continues to wreak havoc in the Democratic Republic of Congo, the scientific community wonders about the after-effects that may remain among survivors. To learn more, researchers from Inserm and Université Paris-Est Créteil at the Institute for Vaccine Research decided to look at how their immune profiles had changed.